TCRT
vs
S&P 500

Over the past 12 months, TCRT has underperformed S&P 500, delivering a return of -36% compared to the S&P 500's 9% growth.
Stocks Performance
TCRT vs S&P 500
Performance Gap
TCRT vs S&P 500
Performance By Year
TCRT vs S&P 500
Alaunos Therapeutics Inc
Glance View
Alaunos Therapeutics, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. The company is headquartered in Houston, Texas and currently employs 41 full-time employees. The company went IPO on 2004-08-20. The firm is focused on discovering, developing, and commercializing immuno-oncology platforms. The firm is engaged in developing technologies that utilize the immune system by employing innovative cell engineering to deliver cell therapies for the treatment of multiple cancer types. The company is focused on developing T-cell receptor (TCR), T cell therapies to target neoantigens in solid tumors (TCR-T). The firm's platform Sleeping Beauty is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that engineers T cells outside of the body for subsequent infusion. The company targets tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR, which are prevalent in gastrointestinal, lung, and gynecological cancers. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.